{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:59:43Z","timestamp":1787065183507,"version":"build-2736575974"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:00:00Z","timestamp":1766793600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.biopha.2025.118948","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T06:34:21Z","timestamp":1767681261000},"page":"118948","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Protecting the endocrine axis in immuno-oncology: GLP-1 receptor agonists as host-directed modulators in colorectal cancer"],"prefix":"10.1016","volume":"194","author":[{"given":"Samira","family":"Saghafi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Ali","family":"Yaghoubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9883-9186","authenticated-orcid":false,"given":"Hossein","family":"Safarpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamideh","family":"Raeisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohreh","family":"Mousavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.biopha.2025.118948_bib1","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41571-024-00943-6","article-title":"Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response","volume":"21","author":"Williams","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118948_bib2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ejca.2023.03.029","article-title":"Tumour mutational burden as a biomarker in patients with mismatch repair deficient\/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors","volume":"187","author":"Manca","year":"2023","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2025.118948_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11523-019-00690-0","article-title":"Immune checkpoint inhibition in colorectal cancer: microsatellite instability and beyond","volume":"15","author":"Cohen","year":"2020","journal-title":"Target Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118948_bib4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s43152-024-00054-5","article-title":"Role of Microsatellite Instability as Pan-Cancer Agnostic Marker of Solid Tumours in Personalized Medicine","volume":"5","author":"Kaler","year":"2024","journal-title":"Curr. Tissue Microenviron. Rep."},{"issue":"5","key":"10.1016\/j.biopha.2025.118948_bib5","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study","volume":"23","author":"Diaz","year":"2022","journal-title":"Lancet Oncol."},{"issue":"23","key":"10.1016\/j.biopha.2025.118948_bib6","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andre","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.biopha.2025.118948_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008689","article-title":"Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study","volume":"12","author":"Overman","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2025.118948_bib8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.19.02107","article-title":"Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164","volume":"38","author":"Le","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118948_bib9","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.3389\/fimmu.2020.02039","article-title":"Crosstalk between the MSI status and tumor microenvironment in colorectal cancer","volume":"11","author":"Lin","year":"2020","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118948_bib10","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12935-023-03183-3","article-title":"Immune checkpoint inhibitors in gastrointestinal malignancies: an umbrella review","volume":"24","author":"Noori","year":"2024","journal-title":"Cancer Cell Int"},{"issue":"2","key":"10.1016\/j.biopha.2025.118948_bib11","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.biopha.2025.118948_bib12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118948_bib13","article-title":"New insight in endocrine-related adverse events associated to immune checkpoint blockade","volume":"34","author":"Elia","year":"2020","journal-title":"Best. Pr. Res Clin. Endocrinol. Metab."},{"issue":"11","key":"10.1016\/j.biopha.2025.118948_bib14","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1007\/s40618-023-02096-2","article-title":"Predictors of thyroid adverse events during cancer immunotherapy: a real-life experience at a single center","volume":"46","author":"Ruggeri","year":"2023","journal-title":"J. Endocrinol. Invest"},{"issue":"1","key":"10.1016\/j.biopha.2025.118948_bib15","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","article-title":"Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights","volume":"19","author":"Faje","year":"2016","journal-title":"Pituitary"},{"issue":"10","key":"10.1016\/j.biopha.2025.118948_bib16","doi-asserted-by":"crossref","first-page":"R207","DOI":"10.1530\/EC-20-0342","article-title":"Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review","volume":"9","author":"Stelmachowska-Banas","year":"2020","journal-title":"Endocr. Connect"},{"issue":"20","key":"10.1016\/j.biopha.2025.118948_bib17","doi-asserted-by":"crossref","first-page":"4974","DOI":"10.3390\/cancers14204974","article-title":"Immune-checkpoint inhibitors (ICIs) in metastatic colorectal cancer (mCRC) patients beyond microsatellite instability","volume":"14","author":"Borelli","year":"2022","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.biopha.2025.118948_bib18","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3390\/cancers15030863","article-title":"Current landscape and potential challenges of immune checkpoint inhibitors in microsatellite stable metastatic colorectal carcinoma","volume":"15","author":"San-Roman-Gil","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.biopha.2025.118948_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005493","article-title":"Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR\/MSI-H metastatic colorectal cancer","volume":"11","author":"Nasca","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2025.118948_bib20","article-title":"Neoadjuvant immunotherapy for MSI-H\/dMMR locally advanced colorectal cancer: new strategies and unveiled opportunities","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2025.118948_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114290","article-title":"BRAF + EGFR +\/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer","volume":"210","author":"Ambrosini","year":"2024","journal-title":"Eur. J. Cancer"},{"issue":"9","key":"10.1016\/j.biopha.2025.118948_bib22","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s00262-024-03764-9","article-title":"Long-term survivals of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy in dMMR\/MSI-H colorectal and gastric cancers","volume":"73","author":"Wang","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"issue":"3","key":"10.1016\/j.biopha.2025.118948_bib23","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s12020-024-04050-5","article-title":"Pathophysiology, diagnosis, and management of immune checkpoint inhibitor-induced diabetes mellitus","volume":"87","author":"Kani","year":"2025","journal-title":"Endocrine"},{"issue":"6","key":"10.1016\/j.biopha.2025.118948_bib24","first-page":"428","article-title":"American Cancer Society Colorectal Cancer Survivorship Care Guidelines","volume":"65","author":"El-Shami","year":"2015","journal-title":"CA Cancer J. Clin."},{"issue":"4_","key":"10.1016\/j.biopha.2025.118948_bib25","article-title":"Efficacy and tolerability of immune checkpoint inhibitors in elderly patients with MSI\/dMMR gastrointestinal cancers and impact of toxicities on efficacy: the immunoMSI cohort","volume":"41","author":"Mailly-Giacchetti","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118948_bib26","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.cpt.2023.11.005","article-title":"Common endocrine system adverse events associated with immune checkpoint inhibitors","volume":"2","author":"Li","year":"2024","journal-title":"Cancer Pathog. Ther."},{"issue":"7","key":"10.1016\/j.biopha.2025.118948_bib27","first-page":"1031","article-title":"Endocrine organ dysfunction with immune-checkpoint inhibitors","volume":"45","author":"Inaba","year":"2018","journal-title":"Gan Kagaku Ryoho"},{"issue":"1","key":"10.1016\/j.biopha.2025.118948_bib28","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3390\/cancers15010246","article-title":"Management of ENdocrine and Metabolic Toxicities of Immune-checkpoint Inhibitors: from Clinical Studies to A Real-life Scenario","volume":"15","author":"Spagnolo","year":"2022","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.biopha.2025.118948_bib29","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.6004\/jnccn.2020.7640","article-title":"Immune-related adverse events (irAEs): implications for immune checkpoint inhibitor therapy","volume":"18","author":"Zhou","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"2","key":"10.1016\/j.biopha.2025.118948_bib30","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2025.118948_bib31","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1634\/theoncologist.2018-0470","article-title":"Endocrine-related adverse events related to immune checkpoint inhibitors: proposed algorithms for management","volume":"25","author":"Del Rivero","year":"2020","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.biopha.2025.118948_bib32","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/jamaoncol.2024.3104","article-title":"Identification of immune checkpoint inhibitor\u2013induced diabetes","volume":"10","author":"Ruiz-Esteves","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.biopha.2025.118948_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.836859","article-title":"Immune checkpoint inhibitor-induced hypophysitis and patterns of loss of pituitary function","volume":"12","author":"Jessel","year":"2022","journal-title":"Front Oncol."},{"key":"10.1016\/j.biopha.2025.118948_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111961","article-title":"Incidence of thyroid dysfunction caused by immune checkpoint inhibitors combined with chemotherapy: a systematic review and meta-analysis","volume":"133","author":"Yang","year":"2024","journal-title":"Int Immunopharmacol."},{"key":"10.1016\/j.biopha.2025.118948_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1093194","article-title":"Adverse events of PD-(L)1 inhibitors plus anti-VEGF(R) agents compared with PD-(L)1 inhibitors alone for cancer patients: a systematic review and meta-analysis","volume":"14","author":"Tang","year":"2023","journal-title":"Front Pharm."},{"issue":"3","key":"10.1016\/j.biopha.2025.118948_bib36","article-title":"Immune checkpoint inhibitor-related thyroid dysfunction","volume":"36","author":"Iwama","year":"2022","journal-title":"Best. Pr. Res Clin. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.biopha.2025.118948_bib37","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1007\/s10238-023-01082-5","article-title":"Immune-related thyroid dysfunctions during anti PD-1\/PD-L1 inhibitors: new evidence from a single centre experience","volume":"23","author":"Nervo","year":"2023","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.biopha.2025.118948_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1584675","article-title":"Immune checkpoint inhibitor-induced thyroiditis and its potential mechanisms","volume":"16","author":"Mao","year":"2025","journal-title":"Front Endocrinol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118948_bib39","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/imr.13247","article-title":"Immune-related adverse events after immune check point inhibitors: understanding the intersection with autoimmunity","volume":"318","author":"Singh","year":"2023","journal-title":"Immunol. Rev."},{"issue":"5","key":"10.1016\/j.biopha.2025.118948_bib40","first-page":"6677","article-title":"Thyroid dysfunction: an autoimmune aspect","volume":"8","author":"Al-Jameil","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"10.1016\/j.biopha.2025.118948_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1190850","article-title":"An updated review of gastrointestinal toxicity induced by PD-1 inhibitors: from mechanisms to management","volume":"14","author":"Cheng","year":"2023","journal-title":"Front Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118948_bib42","doi-asserted-by":"crossref","first-page":"297","DOI":"10.30574\/wjarr.2022.15.2.0819","article-title":"Cancer immunotherapy associated hypophysitis: pathophysiology and management","volume":"15","author":"Sanjib Kumar","year":"2022","journal-title":"World J. Adv. Res. Rev."},{"issue":"4","key":"10.1016\/j.biopha.2025.118948_bib43","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1634\/theoncologist.2011-0404","article-title":"Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease","volume":"17","author":"Torino","year":"2012","journal-title":"Oncologist"},{"issue":"230","key":"10.1016\/j.biopha.2025.118948_bib44","doi-asserted-by":"crossref","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.biopha.2025.118948_bib45","doi-asserted-by":"crossref","first-page":"16","DOI":"10.14341\/probl12777","article-title":"Clinical and radiological diagnosis of hypophysitis: a review of literature and own data","volume":"68","author":"Vorontsov","year":"2022","journal-title":"Probl. Endokrinol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118948_bib46","doi-asserted-by":"crossref","first-page":"R107","DOI":"10.1530\/EJE-19-0169","article-title":"Management of endocrine disease: immune check point inhibitors-induced hypophysitis","volume":"181","author":"Albarel","year":"2019","journal-title":"Eur. J. Endocrinol."},{"issue":"12","key":"10.1016\/j.biopha.2025.118948_bib47","doi-asserted-by":"crossref","first-page":"e967","DOI":"10.1093\/oncolo\/oyac220","article-title":"Recurrence of hypophysitis after immune checkpoint inhibitor rechallenge","volume":"27","author":"Park","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.biopha.2025.118948_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101787","article-title":"Clinical characteristics and treatment efficacy of immune checkpoint inhibitors (ICIs) in patients with ICIs-induced adrenal insufficiency","volume":"38","author":"Xiang","year":"2023","journal-title":"Transl. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118948_bib49","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2018-000591","article-title":"Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes","volume":"7","author":"Kotwal","year":"2019","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"10.1016\/j.biopha.2025.118948_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101473","article-title":"Clinical characteristics and outcomes of immune checkpoint inhibitor-induced diabetes mellitus","volume":"24","author":"Liu","year":"2022","journal-title":"Transl. Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118948_bib51","doi-asserted-by":"crossref","DOI":"10.1093\/lambio\/ovaf060","article-title":"Gut microbiota dysbiosis and the anti-inflammatory effects of probiotic-derived cell-free supernatants in HT-29 cells: insights into early stage colorectal cancer","volume":"78","author":"Erfanian","year":"2025","journal-title":"Lett. Appl. Microbiol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118948_bib52","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s40168-018-0451-2","article-title":"Multi-cohort analysis of colorectal cancer metagenome identified altered bacteria across populations and universal bacterial markers","volume":"6","author":"Dai","year":"2018","journal-title":"Microbiome"},{"key":"10.1016\/j.biopha.2025.118948_bib53","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3389\/fimmu.2019.00277","article-title":"Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases","volume":"10","author":"Parada Venegas","year":"2019","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118948_bib54","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13099-025-00717-0","article-title":"Risk factors and outcomes of Clostridioides difficile infection in patients with colorectal cancer: critical perspective in management","volume":"17","author":"Raeisi","year":"2025","journal-title":"Gut Pathog."},{"issue":"1","key":"10.1016\/j.biopha.2025.118948_bib55","first-page":"68","article-title":"Investigating the therapeutic potential of Bifidobacterium breve and Lactobacillus rhamnosus postbiotics through apoptosis induction in colorectal HT-29 cancer cells","volume":"16","author":"Erfanian","year":"2024","journal-title":"Iran. J. Microbiol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118948_bib56","doi-asserted-by":"crossref","first-page":"22988","DOI":"10.1038\/s41598-023-50047-x","article-title":"Characterization of Wnt signaling pathway under treatment of Lactobacillus acidophilus postbiotic in colorectal cancer using an integrated in silico and in vitro analysis","volume":"13","author":"Erfanian","year":"2023","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.biopha.2025.118948_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/nu15092211","article-title":"Short-chain fatty-acid-producing bacteria: key components of the human gut microbiota","volume":"15","author":"Fusco","year":"2023","journal-title":"Nutrients"},{"issue":"2","key":"10.1016\/j.biopha.2025.118948_bib58","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2023.2249143","article-title":"Microbial metabolite butyrate promotes anti-PD-1 antitumor efficacy by modulating T cell receptor signaling of cytotoxic CD8 T cell","volume":"15","author":"Zhu","year":"2023","journal-title":"Gut Microbes"},{"issue":"3","key":"10.1016\/j.biopha.2025.118948_bib59","article-title":"Gut microbiome and the response to immunotherapy in cancer","volume":"6","author":"Stancu","year":"2018","journal-title":"Discovries"},{"issue":"8","key":"10.1016\/j.biopha.2025.118948_bib60","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/s41591-021-01406-6","article-title":"Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade","volume":"27","author":"Andrews","year":"2021","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.biopha.2025.118948_bib61","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41591-022-01698-2","article-title":"Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1","volume":"28","author":"McCulloch","year":"2022","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.biopha.2025.118948_bib62","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003334","article-title":"Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers","volume":"9","author":"Mao","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2025.118948_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102782","article-title":"GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review","volume":"75","author":"Alfaris","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"4","key":"10.1016\/j.biopha.2025.118948_bib64","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.biopha.2025.118948_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103464","article-title":"Efficacy of lifestyle modification combined with GLP-1 receptor agonists on body weight and cardiometabolic biomarkers in individuals with overweight or obesity: a systematic review and meta-analysis","volume":"88","author":"Chu","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"3","key":"10.1016\/j.biopha.2025.118948_bib66","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","article-title":"Mapping the effectiveness and risks of GLP-1 receptor agonists","volume":"31","author":"Xie","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2025.118948_bib67","first-page":"1","article-title":"GLP-1-based therapies for diabetes, obesity and beyond","author":"Drucker","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"issue":"12","key":"10.1016\/j.biopha.2025.118948_bib68","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1111\/dom.14160","article-title":"Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: results of the LEADER and SUSTAIN 6 trials","volume":"22","author":"Verma","year":"2020","journal-title":"Diabetes Obes. Metab."},{"issue":"10193","key":"10.1016\/j.biopha.2025.118948_bib69","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.biopha.2025.118948_bib70","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.biopha.2025.118948_bib71","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1148209","article-title":"Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent","volume":"14","author":"Mehdi","year":"2023","journal-title":"Front Immunol."},{"issue":"7","key":"10.1016\/j.biopha.2025.118948_bib72","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1111\/dom.16366","article-title":"The effect of GLP-1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: a systematic review and meta-analysis","volume":"27","author":"Ren","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.biopha.2025.118948_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2025.103453","article-title":"Association between autoimmune diseases and glucagon-like peptide-1 receptor agonists: a real-world evidence study","volume":"155","author":"Lee","year":"2025","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.biopha.2025.118948_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106320","article-title":"The anti-inflammatory and immunological properties of GLP-1 receptor agonists","volume":"182","author":"Bendotti","year":"2022","journal-title":"Pharm. Res"},{"issue":"16","key":"10.1016\/j.biopha.2025.118948_bib75","doi-asserted-by":"crossref","DOI":"10.3390\/cells11162587","article-title":"Induced human regulatory T cells express the glucagon-like peptide-1 receptor","volume":"11","author":"Rode","year":"2022","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.biopha.2025.118948_bib76","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s10020-022-00574-6","article-title":"Exenatide regulates Th17\/Treg balance via PI3K\/Akt\/FoxO1 pathway in db\/db mice","volume":"28","author":"Xu","year":"2022","journal-title":"Mol. Med"},{"issue":"5","key":"10.1016\/j.biopha.2025.118948_bib77","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13051128","article-title":"GLP-1R agonists and their therapeutic potential in inflammatory bowel disease and other immune-mediated inflammatory diseases, a systematic review of the literature","volume":"13","author":"Thin","year":"2025","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.biopha.2025.118948_bib78","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.bbrc.2018.12.149","article-title":"Liraglutide protects against inflammatory stress in non-alcoholic fatty liver by modulating Kupffer cells M2 polarization via cAMP-PKA-STAT3 signaling pathway","volume":"510","author":"Li","year":"2019","journal-title":"Biochem Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2025.118948_bib79","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.2147\/DMSO.S537001","article-title":"The effect of semaglutide on gut microbiota in chinese patients with type 2 diabetes poorly controlled by metformin","volume":"18","author":"Chen","year":"2025","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"10.1016\/j.biopha.2025.118948_bib80","article-title":"Gut microbial signatures for glycemic responses of GLP-1 receptor agonists in type 2 diabetic patients: a pilot study","volume":"12","author":"Tsai","year":"2021","journal-title":"Front Endocrinol."},{"key":"10.1016\/j.biopha.2025.118948_bib81","article-title":"Effects of semaglutide on metabolism and gut microbiota in high-fat diet-induced obese mice","volume":"16","author":"Sun","year":"2025","journal-title":"Front Pharm."},{"issue":"7","key":"10.1016\/j.biopha.2025.118948_bib82","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.21305","article-title":"Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.biopha.2025.118948_bib83","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.10507","article-title":"Glucagon-like peptide-1 receptor agonists and incidence of obesity-related cancer in adults with diabetes: a target-trial emulation study","author":"Mavromatis","year":"2025","journal-title":"Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118948_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103213","article-title":"Glucagon-like peptide-1 receptor agonists compared with bariatric metabolic surgery and the risk of obesity-related cancer: an observational, retrospective cohort study","volume":"83","author":"Wolff Sagy","year":"2025","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.biopha.2025.118948_bib85","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.901559","article-title":"Effects of GLP-1 receptor agonists on biological behavior of colorectal cancer cells by regulating PI3K\/AKT\/mTOR signaling pathway","volume":"13","author":"Tong","year":"2022","journal-title":"Front Pharm."},{"key":"10.1016\/j.biopha.2025.118948_bib86","doi-asserted-by":"crossref","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther. Adv. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.biopha.2025.118948_bib87","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.3390\/nu17081303","article-title":"Effects of GLP-1 analogues and agonists on the gut microbiota: a systematic review","volume":"17","author":"Gofron","year":"2025","journal-title":"Nutrients"},{"issue":"7","key":"10.1016\/j.biopha.2025.118948_bib88","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.240303","article-title":"GLP-1\/GLP-1R axis: from metabolism (obesity and T2DM) to immunity","volume":"15","author":"Kumar","year":"2025","journal-title":"Open Biol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118948_bib89","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"issue":"1","key":"10.1016\/j.biopha.2025.118948_bib90","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41467-022-27960-2","article-title":"Immune-related adverse events and the balancing act of immunotherapy","volume":"13","author":"Conroy","year":"2022","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.biopha.2025.118948_bib91","doi-asserted-by":"crossref","DOI":"10.1177\/0300060521992981","article-title":"GLP-1 alleviates NLRP3 inflammasome-dependent inflammation in perivascular adipose tissue by inhibiting the NF-kappaB signalling pathway","volume":"49","author":"Chen","year":"2021","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.biopha.2025.118948_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2021.155654","article-title":"Role of IL-6 in the commitment of T cell subsets","volume":"146","author":"Korn","year":"2021","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.biopha.2025.118948_bib93","doi-asserted-by":"crossref","DOI":"10.3390\/cells12010138","article-title":"The cytokine network in colorectal cancer: implications for new treatment strategies","volume":"12","author":"Braumuller","year":"2022","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.biopha.2025.118948_bib94","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.it.2014.12.004","article-title":"Targeting T cell metabolism for therapy","volume":"36","author":"O'Sullivan","year":"2015","journal-title":"Trends Immunol."},{"issue":"7","key":"10.1016\/j.biopha.2025.118948_bib95","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1158\/2326-6066.CIR-20-0969","article-title":"Regulatory T-cell transcriptomic reprogramming characterizes adverse events by checkpoint inhibitors in solid tumors","volume":"9","author":"Grigoriou","year":"2021","journal-title":"Cancer Immunol. Res."},{"issue":"18","key":"10.1016\/j.biopha.2025.118948_bib96","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.3748\/wjg.v28.i18.1981","article-title":"Fusobacterium nucleatum promotes colon cancer progression by changing the mucosal microbiota and colon transcriptome in a mouse model","volume":"28","author":"Wu","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.biopha.2025.118948_bib97","article-title":"Gut microbial signatures for glycemic responses of GLP-1 receptor agonists in type 2 diabetic patients: a pilot study","volume":"12 - 2021","author":"Tsai","year":"2022","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.biopha.2025.118948_bib98","article-title":"A changed gut microbiota diversity is associated with metabolic improvements after duodenal mucosal resurfacing with glucagon-like-peptide-1 receptor agonist in type 2 diabetes in a pilot study","volume":"3 - 2022","author":"Meiring","year":"2022","journal-title":"Front. Clin. Diabetes Healthc."},{"issue":"1","key":"10.1016\/j.biopha.2025.118948_bib99","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2025.2558071","article-title":"Systemic and gut microbiome changes with metformin and liraglutide in youth-onset type 2 diabetes: the MIGHTY study","volume":"17","author":"Glaros","year":"2025","journal-title":"Gut Microbes"},{"issue":"5","key":"10.1016\/j.biopha.2025.118948_bib100","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2337\/db22-0784","article-title":"Glucagon acting at the GLP-1 receptor contributes to beta-cell regeneration induced by glucagon receptor antagonism in diabetic mice","volume":"72","author":"Wei","year":"2023","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.biopha.2025.118948_bib101","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1038\/s41598-021-83201-4","article-title":"Continuous stimulation of dual-function peptide PGLP-1-VP inhibits the morbidity and mortality of NOD mice through anti-inflammation and immunoregulation","volume":"11","author":"Gao","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2025.118948_bib102","unstructured":"Optimizing Stage 2 T1DM Management: Assessing the Impact of GLP-1Ra on Metabolic Outcomes in Patients Receiving Teplizumab, D. National Institute of, Digestive, and D. Kidney, Editors, 2024."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225011424?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225011424?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T22:31:26Z","timestamp":1769034686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225011424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":102,"alternative-id":["S0753332225011424"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118948","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Protecting the endocrine axis in immuno-oncology: GLP-1 receptor agonists as host-directed modulators in colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118948","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118948"}}